Plasma multi-miRNA models classify Alzheimer's, Parkinson's, and Lewy body dementia.

Overview

1. Department of Anesthesiology & Perioperative Medicine, Oregon Health & Science University, Portland, OR, United States
2. Biostatistics & Design Program, Oregon Health & Science University, Portland, OR, United States
3. Geriatric Research, Education, and Clinical Center, VA Puget Sound Health Care System, Seattle, WA, United States
4. Department of Neurology, University of Washington, Seattle, WA, United States
5. Department of Psychiatry and Behavioral Sciences, University of Washington, Seattle, WA, United States
6. Department of Neurology, Oregon Health & Science University, Portland, OR, United States
7. Parkinson Center and Movement Disorders Program, Oregon Health & Science University, Portland, OR, United States
8. Portland VAMC Parkinson's Disease Research, Education, and Clinical Center, Portland, OR, United States

Abstract

Introduction: Differentiating Alzheimer’s disease (AD) from both Parkinson’s disease (PD) and Lewy body dementia (DLB) is difficult due to their clinical similarities. Plasma biomarkers offer an alternative to neuroimaging and cerebrospinal fluid analysis; however, there are limitations with respect to differential diagnosis of AD, PD, and DLB with current clinical assays.

Methods: Here we used machine learning to assess plasma miRNAs for their specificity in diagnosing AD vs. PD, and DLB. Our multi-center study assayed 57 AD-associated miRNAs in human plasma from 82 cognitively normal controls (NC), 87 AD, 100 PD, and 20 DLB. Predictive models generated by three independent machine learning methods were evaluated by cross-validated ROC curves [cvAUC (bootstrap bias-corrected 95% CI)]. We also used linear discriminant analysis with all 57 miRNAs to identify a model that best separates AD from PD + DLB participants and DLB from AD+PD participants. Further, we used Target prediction and Ingenuity Pathway Analysis to identify highly relevant mRNA targets of the miRNAs.

Results: Individual assessment of the 57 miRNAs identified a subset of 10 miRNAs that were more AD-specific, and 23 miRNAs that were more PD and/or DLB associated. Ridge logistic regression predictive models with the 10 AD-specific miRNAs had good performance for separating AD vs. PD and DLB (cvAUC = 0.77 [0.70, 0.83]) and AD vs. PD (cvAUC = 0.79 [0.71, 0.85]), but not for AD vs. DLB (cvAUC = 0.58 [0.43, 0.79]). By developing a predictive model using data from all 57 miRNAs and elastic-net regression we achieved good separation of AD from PD (cvAUC = 0.80 [0.72, 0.86]) and DLB (cvAUC = 0.77 [0.64, 0.87]) with a subset of six miRNAs (miRs-19a-3p, 22-3p, 92b-3p, 101-3p, 143-3p, 423–5p) identified as the most important to these models. The linear discriminant analysis model achieved very good classification of AD vs. PD + DLB (cvAUC = 0.94 [0.87, 0.97]), PD from AD+DLB (cvAUC = 0.88 [0.80, 0.92]), and DLB from AD+PD (cvAUC = 0.85 [0.78, 0.89]) with miR-26a-5p and 146a-5p being most important for AD vs. PD + DLB, and miR-142-3p and 101-3p being most important for DLB vs. AD+PD. Target prediction and Ingenuity Pathway Analysis with miR-26a-5p, 146a-5p, 142-3p, 101-3p returned highly relevant mRNA targets associated with tauopathy, dementia, and movement disorders.

Discussion: These data demonstrate that predictive modeling using plasma miRNA expression data may improve the differential diagnosis of AD from PD from DLB.

Reproduced under the paper's license (CC BY), from the paper cited above.

Code

The paper links to its data, not to its authors' code: see the Data section.

Tracing map

A tracing map links a paper to the code its authors published: this paper has none, so it has no map.

Data

Datasets cited

• geo:GSE338073, at NCBI GEO; found in “Data availability statement”

Data availability statement

All data used for statistical comparisons in this study, the amplification flag summary by miRNA and experimental group used to select miRNAs for differential expression or differential detection, and the datasets generated for this study are publicly available in the Gene Expression Omnibus Accession site: https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE338073.

Reproduced under the paper's license (CC BY), from the paper cited above.

Versions

The history of this record: each version stored by the harvester or made by a correction of its authors or of the maintainers of its code, and what changed in its facts. The texts of the paper (its abstract, its availability statements) are not part of it; versions that changed only those are not listed.

Version 1, 27 September 2026: the first record

Recorded: type, language, journal, volume, pages, dates, 9 authors, 8 keywords, 2 funders, 73 references.

Cite

This paper

Sandau, U. S., Wiedrick, J. T., McFarland, T. J., Yearout, D., Zabetian, C. P., Hu, S.-C., Tsuang, D. W., Quinn, J. F., & Saugstad, J. A. (2026). Plasma multi-miRNA models classify Alzheimer's, Parkinson's, and Lewy body dementia. Frontiers in aging neuroscience, 18, 1788991. https://doi.org/10.3389/fnagi.2026.1788991

Similar papers

The papers with a page that share the most with this one: the tools found in their code, their categories, datasets, cited references and authors, the rarest counting most.

[1] doi:10.1038/s44328-026-00086-x [code]

Microfluidic nanomagnetically isolated neuron- and astrocyte-derived extracellular vesicles to differentiate Lewy body and Alzheimer's disease.

Journal: Npj biosensing

In common: Alzheimer's / dementia, cellular / molecular, 5 references

[2] doi:10.1177/09727531261420619

A Meta-analysis to Identify Common Key Genes Across Ageing, Alzheimer's and Parkinson's Diseases.

Journal: Annals of neurosciences

In common: Parkinson's, Alzheimer's / dementia, cellular / molecular, 2 references

[3] doi:10.1093/braincomms/fcag277

Distinct brain extracellular vesicle microRNA profiles differ in frontotemporal dementia and Alzheimer's disease.

Journal: Brain communications

In common: Alzheimer's / dementia, cellular / molecular, 2 references

[4] doi:10.3892/ijmm.2026.5849

miR‑223‑3p promotes microglial lactylation and M1 polarization via the FBXW7/Notch1/Hes1/SIRT1 axis.

Journal: International journal of molecular medicine

In common: Alzheimer's / dementia, cellular / molecular, 2 references

[5] doi:10.1093/brain/awaf346

Staging Alzheimer's disease through amyloid and tau PET.

Journal: Brain : a journal of neurology

In common: Alzheimer's / dementia, 2 references

[6] doi:10.1038/s41420-026-03166-z

Hippocampal small RNAs from patients with schizophrenia induce specific cognitive and neural phenotypes in mice.

Journal: Cell death discovery

In common: 2 references

[7] doi:10.3389/frmbi.2026.1834726 [code]

Shotgun metagenomic analysis reveals taxonomic and functional alterations in the gut microbiome across prodromal and symptomatic Lewy body disease.

Journal: Frontiers in microbiomes

In common: Parkinson's, Alzheimer's / dementia, cellular / molecular, 1 reference

[8] doi:10.1002/mds.70265 [code]

Differential Progression of Neuroinflammation in Patients with Isolated Rapid-Eye-Movement Sleep Behavior Disorder.

Journal: Movement disorders : official journal of the Movement Disorder Society

In common: Parkinson's, Alzheimer's / dementia, cellular / molecular, 1 reference

[9] doi:10.1093/hmg/ddag024 [code]

A microbiome quantitative trait locus in SLC39A8 modulates disease severity in synucleinopathy-induced models of Parkinson's disease.

Journal: Human molecular genetics

In common: Parkinson's, cellular / molecular, 1 reference

[10] doi:10.1007/s11033-026-11965-x [code]

Biological pathways related to mirna-125a-5p in behavioral variant of frontotemporal dementia.

Journal: Molecular biology reports

In common: Alzheimer's / dementia, cellular / molecular, 1 reference

Contribute

The authors of this paper can claim it, correct its record and validate its tracing map, and the maintainers of its code (its owner, or a public member of its organization) correct what it says of their repository; anyone signed in can ask for its removal. Every request goes to OSCR's own machine, which answers it; your account page follows them.

Request its removal

To ask OSCR to remove this record, the copies of its authors' scripts or its tracing map, use the removal request page: signed in, you say who you are, what to remove and why, then review and confirm the request. Published rules decide every request (how).

Discussion: questions and error reports about this paper and its code, from signed-in readers and its authors. It opens with sign-in.

Reproductions: reports from readers who ran the authors' code: what they reproduced, with which environment, commit and data. It opens with sign-in.

Activity: what happens around this paper: new versions of its record, its map's validation, discussions and reproductions. It opens with sign-in.